Lives could be saved with hepatitis C treatment

May 18, 2015
Lives could be saved with hepatitis C treatment

In a letter to the Medical Journal of Australia published today, a Monash University-led team is asking for hepatitis C virus patients to gain improved access to drugs to prevent liver related deaths.

Hepatitis C virus (HCV) infection is a major public health burden in Australia, with estimates of 230,000 people chronically infected.

The research team are calling for the government to subsidise a new therapy which has high cure rates, known as direct acting antiviral (DAA) therapy.

Monash University Professor William Sievert said a delay in access to DAA treatment means that thousands of HCV infected patients could die or develop advanced liver disease.

"If we delay just one year, there will be an extra 900 liver related deaths, 800 new cases of cirrhosis and 500 new cases of . These staggering numbers double if we wait for two years," he said.

"During this decade, the therapy should become the norm for the HCV-infected population. However, the high cost of DAA regimens and competing public health priorities may limit the potential impact of new HCV therapies."

Currently, the cost of DAA treatment is out of reach for most HCV patients.

"The large number of liver-related deaths every year caused by HCV places an enormous burden on our health system," said Professor Sievert, Department of Medicine at Monash Medical Centre.

"Our research team modelled how the HCV disease burden and associated health care costs in Australia will increase as the infected population ages."

The team demonstrated that increasing the efficacy of antiviral therapy and the number of patients treated could avert the expected increase in HCV liver related deaths and end stage .

Professor Sievert's team examined the impact of delayed access to DAA treatment by modelling one and two year delays.

"We estimate that if the current treatment regimens continue in Australia, there will be approximately 22,200 liver related deaths between 2014 and 2030," said Professor Sievert.

"However, if DAA treatment is made widely available and accessible through the Pharmaceutical Benefits Scheme (PBS), that number of deaths will decrease to 13,500 in the same time period."

"We believe it is critical to provide patients with access to highly effective to cure HCV infection without delay in order to diminish future HCV-related morbidity and mortality," added Professor Sievert.

Explore further: All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

More information: "HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths." Med J Aust 2015; 202 (9): 479. DOI: 10.5694/mja15.00165

Related Stories

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Hepatitis C screening essential to help catch patients with advanced liver fibrosis

April 25, 2015
Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

Studies show effectiveness of combo treatment for HCV patients with, without cirrhosis

May 5, 2015
In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment ...

New Hepatitis C treatments cost-effective, but only for selected patients, study shows

March 30, 2015
A study led by Boston Medical Center (BMC) researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups ...

Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

April 24, 2015
A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; ...

Hepatitis C common among HIV-positive patients in sub-Saharan Africa

May 5, 2015
A new study has found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

Recommended for you

Two Group A Streptococcus genes linked to 'flesh-eating' bacterial infections

September 22, 2017
Group A Streptococcus bacteria cause a variety of illnesses that range from mild nuisances like strep throat to life-threatening conditions including pneumonia, toxic shock syndrome and the flesh-eating disease formally known ...

Ecosystem approach makes urinary tract infection more treatable

September 22, 2017
The biological term 'ecosystem' is not usually associated with urinary tract infections, but this should change according to Wageningen scientists.

Residents: Frontline defenders against antibiotic resistance?

September 22, 2017
Antibiotic resistance continues to grow around the world, with sometimes disastrous results. Some strains of bacteria no longer respond to any currently available antibiotic, making death by infections that were once easily ...

Investigators may unlock mystery of how staph cells dodge the body's immune system

September 21, 2017
For years, medical investigators have tried and failed to develop vaccines for a type of staph bacteria associated with the deadly superbug MRSA. But a new study by Cedars-Sinai investigators shows how staph cells evade the ...

Superbug's spread to Vietnam threatens malaria control

September 21, 2017
A highly drug resistant malaria 'superbug' from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine—Vietnam's national first-line malaria treatment, ...

Individualized diets for irritable bowel syndrome better than placebo

September 21, 2017
Patients with irritable bowel syndrome who follow individualized diets based on food sensitivity testing experience fewer symptoms, say Yale researchers. Their study is among the first to provide scientific evidence for this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.